Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
NCT00224393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2023-05-30
Summary
The purpose of this study is to evaluate the efficacy of Enbrel in patients with primary systemic Amyloidosis.
Conditions
- Primary Systemic Amyloidosis
Interventions
- DRUG
-
Enbrel
Sponsors & Collaborators
-
The Cleveland Clinic
lead OTHER
Principal Investigators
-
Mohamad A Hussein, MD · The Cleveland Clinic
-
John A Lust, MD, PhD · Mayo Clinic
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-02-28
- Completion
- 2005-08-31
More Related Trials
-
Rituximab in Systemic Sclerosis
NCT01748084 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT02965573 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Galcanezumab in Healthy Participants
NCT02576951 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
NCT06649695 ·Status: RECRUITING ·Phase: PHASE2
-
Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
NCT02590588 ·Status: TERMINATED ·Phase: PHASE2
-
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
NCT06068829 ·Status: UNKNOWN
-
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690 ·Status: RECRUITING ·Phase: PHASE2
-
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
NCT00802815 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
NCT04480450 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
NCT07305974 ·Status: RECRUITING ·Phase: PHASE2
-
Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
NCT02029378 ·Status: UNKNOWN ·Phase: PHASE2
-
Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
NCT06888973 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
A Study of Galcanezumab in Healthy Participants.
NCT02836613 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
NCT02650895 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NM8074 in Patients with Dermatomyositis (DM)
NCT06887738 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of CM313 in Subject With IgA Nephropathy
NCT06830395 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
NCT02053896 ·Status: COMPLETED
-
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT01925209 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Rituximab Treatment of Focal Segmental Glomerulosclerosis
NCT00550342 ·Status: WITHDRAWN ·Phase: PHASE2
-
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
NCT00002849 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
NCT04237987 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2